TCL Archive New benchmark for CCSG award funding will be lowered from 20 percent of NCI research base to 15 percent, the program’s “reality ratio,” Karen Antman tells NCAB. October 8, 2004
TCL Archive Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up December 26, 2014
TCL Archive Trifluridine and Tipiracil Hydrochloride Increase OS, PFS in Phase III Trial July 25, 2014
